Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.55 |
| ▸ | RECQL | P46063 | 5/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.55 |
| ▸ | USP2 | O75604 | 3/20 | 0.55 |
| ▸ | LCK | P06239 | 3/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | FYN | P06241 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31189097 | 1.00 | KDM6B (0.57) | KDM6BKDM4EHSD17B10TDP1RECQL | |
| SCHEMBL11575402 | 1.00 | KDM6B (0.57) | KDM6BKDM4EHSD17B10TDP1RECQL | |
| SCHEMBL11575407 | 1.00 | KDM6B (0.57) | KDM6BKDM4EHSD17B10TDP1RECQL | |
| SCHEMBL22957012 | 0.84 | KDM6B (0.57) | KDM6BKDM4EHSD17B10TDP1RECQL | |
| SCHEMBL21090091 | 0.84 | KDM6B (0.57) | KDM6BKDM4EHSD17B10TDP1RECQL | |
| SCHEMBL30915529 | 0.84 | KDM6B (0.60) | KDM6BKDM4EHSD17B10TDP1RECQL | |
| SCHEMBL29577557 | 0.84 | KDM6B (0.60) | KDM6BKDM4EHSD17B10TDP1RECQL | |
| SCHEMBL2321567 | 0.84 | KDM6B (0.60) | KDM6BKDM4EHSD17B10TDP1RECQL | |
| SCHEMBL3736877 | 0.84 | KDM6B (0.60) | KDM6BKDM4EHSD17B10TDP1RECQL | |
| SCHEMBL30724831 | 0.83 | KDM6B (0.64) | KDM6BKDM4EHSD17B10TDP1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| US-20220288312-A1 | SYSTEMS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS IN PARKINSON DISEASE SUBJECTS | NEURODERM, LTD. (IL) | 2022-09-15 | — | — | US | claimed |
| EP-4057290-A1 | SYSTEMS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS IN PARKINSON DISEASE SUBJECTS | Neuroderm Ltd (IL) | 2022-09-14 | — | — | EP | claimed |
| WO-2022182658-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | claimed |
| EP-3890713-A1 | L-DOPA AND/OR DOPA DECARBOXYLSE INHIBITORS CONJUGATED TO SUGAR FOR THE TREATMENT OF DOPAMINE-RESPONSIVE DISORDERS | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University (IL) | 2021-10-13 | — | — | EP | claimed |
| WO-2020115753-A1 | L-DOPA AND/OR DOPA DECARBOXYLSE INHIBITORS CONJUGATED TO SUGAR FOR THE TREATMENT OF DOPAMINE-RESPONSIVE DISORDERS | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2020-06-11 | — | — | WO | claimed |
| US-9718766-B2 | High penetration drugs and their compositions thereof for treatment of parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2017-08-01 | — | — | US | claimed |
| EP-2994453-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | Techfields Pharma Co., Ltd. (CN) | 2016-03-16 | — | — | EP | claimed |
| US-20160002157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2016-01-07 | — | — | US | claimed |
| US-20110098265-A1 | METHODS FOR REDUCING CRAVINGS AND IMPULSES ASSOCIATED WITH ADDICTIVE AND COMPULSIVE BEHAVIORS | NEUROSCIENCE, INC. (US) | 2011-04-28 | — | — | US | claimed |
| EP-2167066-A2 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS | Chelsea Therapeutics, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| EP-2142185-A2 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | Chelsea Therapeutics, Inc. (US) | 2010-01-13 | — | — | EP | claimed |
| EP-2134335-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | Chelsea Therapeutics, Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| US-20090023705-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS OR ATTENTION DEFICIT DISORDERS | CHELSEA THERAPEUTICS, INC. | 2009-01-22 | — | — | US | claimed |
| WO-2008137923-A2 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS, OR ATTENTION DEFICIT DISORDERS | CHELSEA THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| WO-2008112773-A2 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | CHELSEA THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2008112562-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | CHELSEA THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20080227830-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | CHELSEA THERAPEUTICS, INC. | 2008-09-18 | — | — | US | claimed |
| US-20080221170-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | CHELSEA THERAPEUTICS, INC. | 2008-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | KDM6B 1822/4885KDM4E 2619/4885HSD17B10 3799/4885 |
| US-20080227830-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF NEURALLY MEDIATED HYPOTENSION | ADRA1D, QDPR, ADRA2C | KDM6B 3385/4885KDM4E 3555/4885HSD17B10 1114/4885 |
| US-20160002157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | ABCB1, PARK7, SLC5A7 | KDM6B 3854/4885KDM4E 4485/4885HSD17B10 408/4885 |
| US-20090023705-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF MOOD DISORDERS, SLEEP DISORDERS OR ATTENTION DEFICIT DISORDERS | COMT, DRD2, PNMT | KDM6B 197/4885KDM4E 165/4885HSD17B10 324/4885 |
| US-20080221170-A1 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA | HTR5A, FAAH, MTNR1B | KDM6B 1632/4885KDM4E 940/4885HSD17B10 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.